Introduction. Numerous clinical trials have proven the connection between two glandular organs, in this case, the breast and the thyroid gland. The occurrence of breast cancer (BC) is increased in patients with autoimmune thyroid disease (Hashimoto's thyroiditis and Graves' disease). Patients with Graves' disease have a significantly smaller number of described cases of BC than those with diagnosed Hashimoto's thyroiditis. Case report. A 57-year-old female patient came to the emergency center with difficulty breathing. During the examination, ophthalmopathy, weakened breath sound and mastitis of both breasts were found. Hormonal analysis showed the following values: TSH 0.00 (0.3-5.5 mlU/L), FT4 32.90 (11.5-23 pmol/L), TSHRAt 19 (0.0-1.1 U/L), TPOAt 234 (0.0-12 IU/ml), TgAt > 2000 (0.0-30.0 IU/ml). A diagnosis of Graves' disease was established and therapy with thyrosuppressant was started immediately. A multi-detector computed tomography (MDCT) showed a left breast tumor with metastases in the supraclavicular and axillary lymph nodes, infiltration of the tumor into the skin and subcutaneous tissue, as well as metastases in the bones. A biopsy of the breast tumor was performed, and PH findings indicated poorly differentiated ductal carcinoma of the breast, the HER-2+ group of tumors. Conclusion. The early detection of thyroid disease would not lead to the development of a malignant process, and that is why doctors in their clinical work must recognize the first signs of thyroid disease in their patients and immediately start with therapy to reduce the potential risk of BC. There is a significant role in using screening tests to discover breast cancer in patients with untreated or inadequately treated hypo-and hyperthyroidism.
References
1.
Shu X, Ji J, Li X, Sundquist J, Sundquist K, Hemminki K. Cancer risk in patients hospitalised for Graves’ disease: a population-based cohort study in Sweden. British Journal of Cancer. 2010;102(9):1397–9.
2.
Martínez-Iglesias O, García-Silva S, Regadera J, Aranda A. Hypothyroidism Enhances Tumor Invasiveness and Metastasis Development. PLoS ONE. 4(7):e6428.
3.
Hoemaker JP, Dagher RK. Remissions of mammary adenocarcinoma in hypothyroid mice given 5-fluorouracil and chloroquine phosphate. J Natl Cancer Inst. 1979;62:1575–8.
4.
Vonderhaar BK, Greco AE. Effect of thyroid status on development of spontaneous mammary tumors in primiparous C3H mice. Cancer Res. 1982;42:4553–61.
5.
Morris HP, Dubnik CS, Dalton AJ. Effect of prolonged ingestion of thiourea on mammary glands and the appearance of mammary tumors in adult C3H mice. J Natl Cancer Inst. 1946;7:159–69.
6.
Fang Y, Yao L, Sun J, Yang R, Chen Y, Tian J, et al. Does thyroid dysfunction increase the risk of breast cancer? A systematic review and meta-analysis. Journal of Endocrinological Investigation. 2017;40(10):1035–47.
7.
Kapdi CC. Breast Cancer. JAMA. 1976;236(10):1124.
8.
Kitahara CM, Berrington de Gonzalez A, Bouville A, Brill AB, Doody MM, Melo DR, et al. Association of Radioactive Iodine Treatment With Cancer Mortality in Patients With Hyperthyroidism. JAMA Internal Medicine. 2019;179(8):1034.
9.
De Leo S, Lee SY, Braverman LE. Hyperthyroidism. The Lancet. 2016;388(10047):906–18.
10.
Chen YK, Lin CL, Chang YJ, Cheng FTF, Peng CL, Sung FC, et al. Cancer Risk in Patients with Graves’ Disease: A Nationwide Cohort Study. Thyroid. 2013;23(7):879–84.
11.
Shi XZ, Xue L, Jin X, Xu P, Jia S, Shen HM. Different expression of sodium–iodide importer (NIS) between lactating breast and thyroid tissues may be due to structural difference of thyroid-stimulating hormone receptor (TSHR). Journal of Endocrinological Investigation. 2017;40(1):41–8.
12.
Fierabracci P, Pinchera A, Campani D, Pollina LE, Giustarini E, Giani C. Association between breast cancer and autoimmune thyroid disorders: no increase of lymphocytic infiltrates in breast malignant tissues. Journal of Endocrinological Investigation. 2006;29(3):248–51.
13.
Davis PJ, Goglia F, Leonard JL. Nongenomic actions of thyroid hormone. Nature Reviews Endocrinology. 2016;12(2):111–21.
14.
Lin HY, Chin YT, Shih YJ, Chen YR, Leinung M, Keating KA, et al. In tumor cells, thyroid hormone analogues non-immunologically regulate PD-L1 and PD-1 accumulation that is anti-apoptotic. Oncotarget. 2018;9(75):34033–7.
15.
Trinh LN, Crawford AR, Hussein MH, Zerfaoui M, Toraih EA, Randolph GW, et al. Deciphering the Risk of Developing Second Primary Thyroid Cancer Following a Primary Malignancy—Who Is at the Greatest Risk? Cancers. 13(6):1402.
16.
Szychta P, Szychta W, Lewiński A, Karbownik-Lewińska M. Co-existence of chronic non-communicable diseases and common neoplasms among 2,462 endocrine adult inpatients – a retrospective analysis. Annals of Agricultural and Environmental Medicine. 2015;22(4):747–54.
17.
Ellerhorst JA, Sendi-Naderi A, Johnson MK, Cooke CP, Dang SM, Diwan AH. Human melanoma cells express functional receptors for thyroid-stimulating hormone. Endocrine-Related Cancer. 2006;13(4):1269–77.
18.
Govindaraj V, Yaduvanshi NS, Krishnamachar H, Rao AJ. Expression of thyroid-stimulating hormone receptor, octamer-binding transcription factor 4, and intracisternal A particle-promoted polypeptide in human breast cancer tissues. hmbci. 2012;9(3):173–8.
19.
Tosovic A, Becker C, Bondeson A, Bondeson L, Ericsson U, Malm J, et al. Prospectively measured thyroid hormones and thyroid peroxidase antibodies in relation to breast cancer risk. International Journal of Cancer. 2012;131(9):2126–33.
20.
Jiskra J, Barkmanova J, Limanova Z, Lanska V, Smutek D, Potlukova E, et al. Thyroid autoimmunity occurs more frequently in women with breast cancer compared to women with colorectal cancer and controls but it has no impact on relapse-free and overall survival. Oncology Reports.
21.
Giani C, Fierabracci P, Bonacci R, Gigliotti A, Campani D, De Negri F, et al. Relationship between breast cancer and thyroid disease: relevance of autoimmune thyroid disorders in breast malignancy. The Journal of Clinical Endocrinology & Metabolism. 1996;81(3):990–4.
22.
Pan XF, Ma YJ, Tang Y, Yu M miao, Wang H, Fan Y ren. Breast cancer populations may have an increased prevalence of thyroglobulin antibody and thyroid peroxidase antibody: a systematic review and meta-analysis. Breast Cancer. 2020;27(5):828–36.
23.
Chen S, Wu F, Hai R, You Q, Xie L, Shu L, et al. Thyroid disease is associated with an increased risk of breast cancer: a systematic review and meta-analysis. Gland Surgery. 2021;10(1):336–46.
24.
Davis PJ, Leonard JL, Davis FB. Mechanisms of nongenomic actions of thyroid hormone. Frontiers in Neuroendocrinology. 2008;29(2):211–8.
25.
Hall LC, Salazar EP, Kane SR, Liu N. Effects of thyroid hormones on human breast cancer cell proliferation. The Journal of Steroid Biochemistry and Molecular Biology. 2008;109(1–2):57–66.
26.
Tosovic A, Becker C, Bondeson A, Bondeson L, Ericsson U, Malm J, et al. Prospectively measured thyroid hormones and thyroid peroxidase antibodies in relation to breast cancer risk. International Journal of Cancer. 2012;131(9):2126–33.
27.
Mahmood S, Vu K, Tai P. Radiation-induced second malignancies. Anticancer Res. 2015;35:2431–4.
28.
Szychta P, Szychta W, Gesing A, Lewiński A, Karbownik-Lewińska M. TSH receptor antibodies have predictive value for breast cancer – retrospective analysis. Thyroid Research. 2013;6(1).
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
,
